BMRN Biomarin Pharmaceutical Inc

Price (delayed)

$77.04

Market cap

$14.08B

P/E Ratio

17.55

Dividend/share

N/A

EPS

$4.39

Enterprise value

$14.49B

Highlights
BMRN's quick ratio has surged by 125% year-on-year and by 12% since the previous quarter
BMRN's P/E is 70% below its last 4 quarters average of 57.6
The debt is up by 26% year-on-year
BMRN's gross margin is down by 10% year-on-year

Key stats

What are the main financial stats of BMRN
Market
Shares outstanding
182.74M
Market cap
$14.08B
Enterprise value
$14.49B
Valuations
Price to earnings (P/E)
17.55
Price to book (P/B)
3.37
Price to sales (P/S)
7.59
EV/EBIT
N/A
EV/EBITDA
1,119.32
EV/Sales
7.85
Earnings
Revenue
$1.84B
EBIT
-$94.25M
EBITDA
$12.94M
Free cash flow
$114.81M
Per share
EPS
$4.39
Free cash flow per share
$0.63
Book value per share
$22.89
Revenue per share
$10.15
TBVPS
$28.62
Balance sheet
Total assets
$5.81B
Total liabilities
$1.64B
Debt
$1.08B
Equity
$4.16B
Working capital
$1.86B
Liquidity
Debt to equity
0.26
Current ratio
5.32
Quick ratio
3.45
Net debt/EBITDA
31.59
Margins
EBITDA margin
0.7%
Gross margin
71.1%
Net margin
43.1%
Operating margin
-6.3%
Efficiency
Return on assets
13.8%
Return on equity
20.4%
Return on invested capital
-1.9%
Return on capital employed
-1.8%
Return on sales
-5.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BMRN stock price

How has the Biomarin Pharmaceutical stock price performed over time
Intraday
-1.81%
1 week
-2.28%
1 month
-6.71%
1 year
-38.12%
YTD
-12.15%
QTD
-7.67%

Financial performance

How have Biomarin Pharmaceutical's revenue and profit performed over time
Revenue
$1.84B
Gross profit
$1.31B
Operating income
-$116.64M
Net income
$795.09M
Gross margin
71.1%
Net margin
43.1%
BMRN's gross margin is down by 10% year-on-year
Biomarin Pharmaceutical's gross profit has decreased by 8% YoY
The net margin is down by 7% since the previous quarter
The net income has declined by 7% since the previous quarter

Growth

What is Biomarin Pharmaceutical's growth rate over time

Valuation

What is Biomarin Pharmaceutical stock price valuation
P/E
17.55
P/B
3.37
P/S
7.59
EV/EBIT
N/A
EV/EBITDA
1,119.32
EV/Sales
7.85
BMRN's P/E is 70% below its last 4 quarters average of 57.6
Biomarin Pharmaceutical's EPS has decreased by 8% QoQ
The stock's price to book (P/B) is 34% less than its 5-year quarterly average of 5.1 and 23% less than its last 4 quarters average of 4.4
The equity has grown by 28% YoY
BMRN's price to sales (P/S) is 28% less than its 5-year quarterly average of 10.6 and 15% less than its last 4 quarters average of 8.9
The revenue has grown by 2.2% YoY

Efficiency

How efficient is Biomarin Pharmaceutical business performance
Biomarin Pharmaceutical's ROIC has plunged by 186% YoY
The ROE has contracted by 13% from the previous quarter
BMRN's return on assets is down by 12% since the previous quarter

Dividends

What is BMRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BMRN.

Financial health

How did Biomarin Pharmaceutical financials performed over time
BMRN's quick ratio has surged by 125% year-on-year and by 12% since the previous quarter
The company's current ratio has surged by 106% YoY and by 12% QoQ
The debt is 74% smaller than the equity
The equity has grown by 28% YoY
The debt is up by 26% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.